GOSS - Gossamer ends development of phase 1 lymphoma candidate after clinical hold

2023-04-03 17:16:58 ET

• Gossamer Bio ( NASDAQ: GOSS ) is ending development of phase 1 CNS lymphoma candidate GB5121 after the US FDA placed a partial clinical hold on all trials.
• The company said the hold is due to serious adverse events that have been observed in the Phase 1b/2 STAR-CNS study, such as atrial fibrillation, a sudden death event and a fatal intracranial hemorrhage.
• In March, Gossamer ( GOSS ) said it had paused enrollment in that study .
• The company closed down 11% on Monday, but is unchanged in after-hours trading.
• Read why Seeking Alpha contributor Avisol Capital Partners issued a sell rating on Gossamer ( GOSS ) at the end of February.

For further details see: